Flu Vaccines, Increased Focus On Preventive Medicine Pique J&J's Interest In Crucell
Executive Summary
If its $2.4 billion bid to buy Crucell N.V. succeeds, Johnson & Johnson will have managed to take a quick leap forward in the vaccines space, going overnight from a non-player to the number six company in the space, behind market leaders GlaxoSmithKline, Merck, Pfizer, Sanofi-Aventis and Novartis.